SCHEMBL4309684

SCHEMBL4309684

O=C(O)c1cccc(C23CC4CC(CC(C4)C2)C3)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
RARA P10276 4/20 0.44
RARB P10826 4/20 0.44
RARG P13631 3/20 0.44
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
HSD17B10 Q99714 3/20 0.43
ALB P02768 1/20 0.43
MMP2 P08253 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 2/20 0.43
ALOX12 P18054 2/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
THRB P10828 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18040211 0.85 RARB (0.45) KDM4ERARARARBRARGALDH1A1
SCHEMBL5475249 0.85 KDM4E (0.53) KDM4ERARARARBRARGALDH1A1
SCHEMBL548737 0.82 MEN1 (0.46) KDM4ERARARARBRARGALDH1A1
SCHEMBL5834020 0.81 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10KMT2A
Phenol SCHEMBL27448237 0.81 HIF1A (0.45) KDM4ERARARARBRARGALDH1A1
SCHEMBL3823755 0.80 KDM4E (0.43) KDM4ERARARARBRARGALDH1A1
SCHEMBL18155724 0.80 RARB (0.44) KDM4ERARARARBRARGALDH1A1
SCHEMBL18040209 0.79 KDM4E (0.49) KDM4ERARARARBRARGALDH1A1
SCHEMBL3759976 0.78 MEN1 (0.46) KDM4ERARARARBRARGALDH1A1
SCHEMBL15766044 0.77 SELL (0.47) KDM4ERARARARBRARGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734208-B2 ADJUSTMENT TRANSFORMING GROWTH FACTOR CONCENTRATION; ANTIINFLAMMATORY AGENTS NEORX CORPORATION 2004-05-11 US claimed
CN-107427431-B Antioxidant or anti-aging composition comprising 5-adamantan-1-yl-N- (2, 4-dihydroxybenzyl) -2, 4-dimethoxybenzamide 株式会社爱茉莉太平洋 2021-04-13 CN disclosed
EP-3278790-B1 ANTI-OXIDATIVE OR ANTI-AGING COMPOSITION CONTAINING 5-ADAMANTAN-1-YL-N-(2,4-DIHYDROXYBENZYL)-2,4-DIMETHOXYBENZAMIDE AMOREPACIFIC CORP (KR) 2021-03-24 EP disclosed
US-20180116933-A1 ANTI-OXIDATIVE OR ANTI-AGING COMPOSITION CONTAINING 5-ADAMANTAN-1-YL-N-(2,4-DIHYDROXYBENZYL)-2,4-DIMETHOXYBENZAMIDE AMOREPACIFIC CORPORATION (KR) 2018-05-03 US disclosed
EP-3278790-A2 ANTI-OXIDATIVE OR ANTI-AGING COMPOSITION CONTAINING 5-ADAMANTAN-1-YL-N-(2,4-DIHYDROXYBENZYL)-2,4-DIMETHOXYBENZAMIDE Amorepacific Corporation (KR) 2018-02-07 EP disclosed
CN-107427431-A Include the anti-oxidant or anti-staling composition of 5 adamantane 1 base N (2,4 dihydroxy benzyl) 2,4 dimethoxybenzarnides 株式会社爱茉莉太平洋 2017-12-01 CN disclosed
US-9433593-B1 Composition for anti-inflammation containing 5-adamantan-1-yl-N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-benzamide AMOREPACIFIC CORPORATION (KR) 2016-09-06 US disclosed
CN-103702977-B Benzoic acid amide compound 株式会社爱茉莉太平洋 2016-08-17 CN disclosed
CN-103702977-A Novel benzoic acid amide compound AMORE PACIFIC CORP 2014-04-02 CN disclosed
US-7511070-B2 Compounds and therapies for the prevention of vascular and non-vascular pathologies PONIARD PHARMACEUTICALS, INC. (US) 2009-03-31 US disclosed
US-7084171-B2 Compounds and therapies for the prevention of vascular and non-vascular pathologies NEORX CORPORATION (US) 2006-08-01 US disclosed
US-20060084696-A1 Compounds and therapies for the prevention of vascular and non-vascular pathologies PONIARD PHARMACEUTICALS, INC. 2006-04-20 US disclosed
US-20050020667-A1 Compounds and therapies for the prevention of vascular and non-vascular pathologies PONIARD PHARMACEUTICALS, INC. 2005-01-27 US disclosed
US-6734208-B2 ADJUSTMENT TRANSFORMING GROWTH FACTOR CONCENTRATION; ANTIINFLAMMATORY AGENTS NEORX CORPORATION 2004-05-11 US disclosed
US-20030064970-A1 Compounds and therapies for the prevention of vascular and non-vascular pathologies NEORX CORPORATION 2003-04-03 US disclosed
US-6410587-B1 FIBROSIS; ALZHEIMER'S DISEASE; ANTIARTHRITIC AGENTS NEORX CORPORATION 2002-06-25 US disclosed
US-6117911-A ADMINISTRATION OF AT LEAST ONE THERAPEUTIC AGENT THAT ELEVATES THE LEVEL OF TGF-BETA IN SAID MAMMAL. NEORX CORPORATION (US) 2000-09-12 US disclosed
WO-1998046588-A2 COMPOUNDS AND THERAPIES FOR THE PREVENTION OF VASCULAR AND NON-VASCULAR PATHOLOGIES NEORX CORPORATION (US) 1998-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084696-A1 Compounds and therapies for the prevention of vascular and non-vascular pathologies TGFB1, TGFB2, TEK KDM4E 3256/4885RARA 1385/4885RARB 527/4885
US-20050020667-A1 Compounds and therapies for the prevention of vascular and non-vascular pathologies TGFB1, TGFB2, TEK KDM4E 3256/4885RARA 1385/4885RARB 527/4885
US-20180116933-A1 ANTI-OXIDATIVE OR ANTI-AGING COMPOSITION CONTAINING 5-ADAMANTAN-1-YL-N-(2,4-DIHYDROXYBENZYL)-2,4-DIMETHOXYBENZAMIDE MMP14, DNASE1, MMP15 KDM4E 515/4885RARA 2089/4885RARB 1643/4885
US-20030064970-A1 Compounds and therapies for the prevention of vascular and non-vascular pathologies TGFB1, TGFB2, TEK KDM4E 3256/4885RARA 1385/4885RARB 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.